ENTER


Полный размерЗакрыть

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Details
Written by Super User
Category: #1 (08) 2018
Published: 16 October 2018
Hits: 2215

Hepsen I. F.1, Ozkaya E.2


1Fatih University Medical School, Ankara, Turkey
2Inonu University Medical School, Malatya, Turkey

ABSTRACT

Purpose. To compare the 24-h IOP reductions induced by latanoprost, travoprost, and bimatoprost in eyes with exfoliation syndrome (XFS) associated with ocular hypertension (OH).

Methods. This was a prospective, randomized, single masked, and parallel design study with 15 patients in each treatment group. After washout of any previous medications, each patient underwent a baseline 24-h IOP curve testing at 06:00, 09:00, 12:00, 15:00, 18:00, 21:00, and at 24:00 (midnight) hours. Patients were then randomized to receive latanoprost, travoprost, or bimatoprost once a day for 3 months. The 24-h curve testing was repeated at first week, and first and third months.

Results. Maximal and minimal IOP was recorded at 06:00 and 18:00–21:00 hours. There was no significant difference among treatment groups at any time-point except for the first week. At the first week, the travoprost group had significantly lower IOP levels than the latanoprost and bimatoprost groups. All medicines significantly lowered 24-h IOP from baseline (P = 0.001 for each). Although there was no significant difference in IOP reduction among groups at first week and first month, bimatoprost reduced the 24-h IOP (7.9 ± 1.4) more than travoprost (6.6 ± 0.5) at the end of the third month (P = 0.003). The mean 24-h range of IOP was lowest with travoprost in all visits, and between-group differences was significant for travoprost vs latanoprost (P = 0.007) and travoprost vs bimatoprost (P = 0.001) at the third month.

Conclusion. Latanoprost, travoprost, and bimatoprost were effective in reducing the 24-h IOP in patients with XFS and OH, and more research is required with a larger study.

Keywords: exfoliation syndrome; 24-h IOP; latanoprost; travoprost; bimatoprost.


REFERENCES

  1. Bergea B, Bodin L, Svedberg B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997–1005.
  2. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142.
  3. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182–185.
  4. Konstas AG, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:975–979.
  5. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55.
  6. O’Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic openangle glaucoma. Am J Ophthalmol. 1991;111:491–500.
  7. Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004; 18:1264–1269.
  8. Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye. 2003;17:41–46.
  9. Konstas AG, Lake S, Maltezos AC, Holmes KT, Stewart WC. Twenty-four-hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye. 2001;15:59–62.
  10. Larsson LI. Intraocular pressure over 24 h after repeated administration of latanoprost 0.005% or timolol gelforming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439–1444.
  11. Larsson LI. Intraocular pressure over 24 h after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, crossover single center study. Acta Ophthalmol Scand. 2001;79:567–571.
  12. Mishima HK, Kiuchi Y, Takamatsu M, Racz P, Bito LZ. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997;41(Suppl 2):P139–P144.
  13. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest ophthalmol Vis Sci. 2000;41:2566–2573.
  14. Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262–266.
  15. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–2917.
  16. Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39:2707–2712.
  17. Konstas AG. Therapeutic implication of IOP and OBF (scientific symposium). World Glaucoma Congress 6 July, 2005, Vienna, Austria.
  18. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol. 2005; 139:320–324.
  19. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898–902.
  20. Parrish RK, Palmberg P, Sheu W-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003;135:688–703.
  21. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. Bimatoprost Circadian IOP Study group. 24-h IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(Suppl 1):P26–P35.
  22. Hughes E, Spry P, Diamond J. 24-h monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12:232–236.

Hepsen I, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye. 2007;21:453–8.

Translation from English.

Republished: September 2018